Allergan announced the approval of Rhofade cream (oxymetazoline HCI cream 1.0%) by the U.S. FDA for the topical treatment of...
Dipexium Pharmaceuticals, Inc. announced that the OneStep-1 and OneStep-2 Phase III clinical trials of Locilex (pexiganan cream 0.8%) in patients...
Allergan announced that the New Drug Application filing for AGN 199201 (oxymetazoline HCl cream 1.0%) an investigational topical prescription product...
Incyte and Maruho Co., Ltd. announced that the companies have entered into a Strategic Alliance Agreement for the development, manufacturing and exclusive commercialization of ruxolitinib cream, a novel cream formulation of Incyte's selective JAK2 inhibitor ruxolitinib, for treatment of autoimmune and inflammatory dermatology indications in Japan.
Incyte Biosciences has announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation for Opzelura cream.
Galderma announced that the FDA approved Aklief (trifarotene) Cream, 0.005% for the topical treatment of acne. Trifarotene is the first...